title: Respiratory reviews in asthma 2013.
abstract: From January 2012 up until March 2013, many articles with huge clinical importance in asthma were published based on large numbered clinical trials or meta-analysis. The main subjects of these studies were the new therapeutic plan based on the asthma phenotype or efficacy along with the safety issues regarding the current treatment guidelines. For efficacy and safety issues, inhaled corticosteroid tapering strategy or continued long-acting beta agonists use was the major concern. As new therapeutic trials, monoclonal antibodies or macrolide antibiotics based on inflammatory phenotypes have been under investigation, with promising preliminary results. There were other issues on the disease susceptibility or genetic background of asthma, particularly for the "severe asthma" phenotype. In the era of genome and pharmacogenetics, there have been extensive studies to identify susceptible candidate genes based on the results of genome wide association studies (GWAS). However, for severe asthma, which is where most of the mortality or medical costs develop, it is very unclear. Moreover, there have been some efforts to find important genetic information in order to predict the possible disease progression, but with few significant results up until now. In conclusion, there are new on-going aspects in the phenotypic classification of asthma and therapeutic strategy according to the phenotypic variations. With more pharmacogenomic information and clear identification of the "severe asthma" group even before disease progression from GWAS data, more adequate and individualized therapeutic strategy could be realized in the future.
authors.affiliation: Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Seoul, Korea.
authors.forename: Tae-Hyung
authors.initials: TH
authors.lastname: Kim
keywords: Asthma; Pharmacogenetics; Phenotype; Therapeutics
references.citation: N Engl J Med. 2012 Sep 27;367(13):1198-207
references.pmid: 22938706
references.citation: Thorax. 2012 Sep;67(9):762-8
references.pmid: 22561531
references.citation: J Allergy Clin Immunol. 2012 Aug;130(2):510-5.e1
references.pmid: 22554704
references.citation: Chest. 2012 Jan;141(1):66-72
references.pmid: 21868465
references.citation: Arch Intern Med. 2012 Oct 8;172(18):1365-75
references.pmid: 22928176
references.citation: Lancet. 2012 Aug 18;380(9842):651-9
references.pmid: 22901886
references.citation: Chest. 2012 Jan;141(1):58-65
references.pmid: 21885725
references.citation: J Allergy Clin Immunol. 2012 Sep;130(3):647-654.e10
references.pmid: 22857879
references.citation: Thorax. 2013 Apr;68(4):322-9
references.pmid: 23291349
references.citation: JAMA. 2012 Sep 12;308(10):987-97
references.pmid: 22968888
references.citation: J Allergy Clin Immunol. 2012 Nov;130(5):1071-1077.e10
references.pmid: 23036744
references.citation: J Allergy Clin Immunol. 2010 Oct;126(4):747-53
references.pmid: 20920764
references.citation: N Engl J Med. 2009 Mar 5;360(10):973-84
references.pmid: 19264686
references.citation: N Engl J Med. 2011 Aug 25;365(8):689-98
references.pmid: 21864166
references.citation: J Allergy Clin Immunol. 2012 May;129(5):1274-1279.e2
references.pmid: 22281166
references.citation: J Allergy Clin Immunol. 2012 Jul;130(1):69-75.e6
references.pmid: 22465214